Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBT021601 Phase 1 in Healthy Participants
NCT05036512Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2020
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in sickle cell disease (SCD) comparing GBT021601 with Placebo (2 arms). Primary endpoints: Frequency and severity of adverse events at 134 days, Changes in Heart Rate at 134 days and 4 more. Started Dec 2020; status: completed.
02
Drugs
osivelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05036512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05036512.